Back to News
Market Impact: 0.32

Keros Therapeutics Authorises $ 5 Mln Share Buyback Following Elritercept Milestone; Stock Up

Source: Nasdaq

Capital Returns (Dividends / Buybacks)Healthcare & BiotechCompany Fundamentals

Keros Therapeutics' board approved a $5 million share-repurchase program after the clinical-stage biotech received a $20 million elritercept milestone payment from partner Takeda Pharmaceuticals. The buyback represents 25% of the milestone proceeds and signals management confidence while returning part of the partnership-related cash inflow to shareholders.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

moderately positive

Sentiment Score

0.42

Ticker Sentiment

KROS0.58

More News